Abstract
Heparan sulphate is an important mediator in determining vascular smooth muscle cell (SMC) phenotype. The sulphation pattern of the heparan sulphate chains is critical to their function. We have examined the initial step in the biosynthesis of the sulphated domains mediated by the enzyme heparan sulphate N-deacetylase/N-sulphotransferase (NDST). Rabbit aortic SMC in primary culture exhibited NDST enzyme activity and expressed NDST-1 in their Golgi apparatus, with maximal expression in SMC 2 days after dispersal in primary culture confirmed by Western blot analysis. Endothelial cells, macrophages and fibroblasts expressed NDST-1 but had generally less intense staining than SMC, although SMC expression decreased with culture. The uninjured rat aorta also showed widespread expression of NDST-1. After balloon de-endothelialisation, NDST-1 could not be detected in SMC of the neointima in the early stages of neointimal formation, but was re-expressed at later time points (after 12 weeks). In human coronary arteries, SMC of the media and the diffuse intimal thickening expressed NDST-1, while SMC in the atherosclerotic plaque were negative for NDST-1. We conclude that SMC may regulate their heparan sulphate sulphation at the level of expression of the enzyme heparan sulphate NDST in a manner related to their phenotypic state.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aikawa J, Esko J (1999) Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNac N-deacetylase/ N-sulfotransferase family. J Biol Chem 274: 2690–2695.
Aikawa J, Grobe K, Tsujimoto M, Esko J (2001) Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. J Biol Chem 276: 5876–5882.
Bingley JA, Hayward IP, Campbell GR, Campbell JH (2001) Relationship of glycosaminoglycan and matrix changes to vascular smooth muscle cell phenotype modulation in rabbit arteries following acute injury. J Vasc Surg 33: 155–164.
Bingley JA, Hayward IP, Campbell JH, Campbell GR(1998) Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 28: 308–318.
Campbell GR, Campbell JH (1987) Phenotypic modulation of smooth muscle cells in primary culture. In: Campbell JH, Campbell GR, eds. Vascular Smooth Muscle in Culture. Boca Raton: CRC Press, pp 39–56.
Campbell JH, Campbell GR (1993) Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci 85: 510–513.
Campbell JH, Rennick RE, Kalevitch SG, Campbell GR (1992) Heparan sulphate-degrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res 200: 156–167.
Castellot JJ, Wright TC, Karnovsky MJ (1987) Regulation of vascular smooth muscle cell growth by heparin and heparan sulfate. Sem Thromb Haem 13: 489–503.
Clowes AW, Karnovsky MJ (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265: 625–626.
Dalferes ER, Radhakrishnamurthy B, Ruiz H, Berenson GS (1987) Composition of proteoglycans from human atherosclerotic lesions. Exp Molec Pathol 47: 363–376.
David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H (1992) Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol 119: 961–975.
Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108: 169–173.
Fan G, Xiao L, Cheng L,Wang X, Sun B, Gengxi H (2000) Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett 467: 7–11.
Fritze LMS, Reilly CF, Rosenberg RD (1985) An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 100: 1041–1049.
Girjes AA, Keriakous D, Hayward IP, Campbell GR, Campbell JH (2001) Cloning of genes differentially regulated during change in vascular smooth muscle phenotype. FEBS Lett 509: 341–342.
Hein M, Fischer J, Kim DK, Hein L, Pratt RE (1996) Vascular smooth muscle cell phenotype influences glycosaminoglycan composition and growth effects of extracellular matrix. J Vasc Res 33: 433–441.
Hollmann J, Schmidt A, von Bassewitz D-B, Buddecke E (1989) Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta. Arteriosclerosis 9: 154–158.
Hoover RL, Rosenberg R, Haering W, Karnovsky MJ (1980) Inhibition of rat arterial smooth muscle cell proliferation by heparin II. In vitro studies. Circ Res 47: 578–583.
Humphries DE, Sullivan BM, Aleixo MD, Stow JL (1997) Localization of human heparan glycosaminyl N-deacetylase/N-sulphotransferase to the trans-Golgi network. Biochem J 325: 351–357.
Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu W, Huang C, Sharpe AH, Stevens RL (1999) Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400: 769–772.
Li Z-Y, Hirayoshi K, Suzuki Y (2000) Expression of N-deacetylase/ sulfotransferase and 3-O-sulfotransferase in rat alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 279: L292–L301.
Lindahl U, Kusche M, Lidholt K, Oscarrson LG (1989) Biosynthesis of heparin and heparan sulfate. In: Lane DA, Lindahl U, eds. Heparin. London: Arnold, pp 548–574.
Manderson JA, Mosse PRL, Safstrom JA, Young SB, Campbell GR (1989) Balloon catheter injury to rabbit carotid artery. I. Changes in smooth muscle cell phenotype. Arteriosclerosis 9: 289–298.
Mosse PRL, Campbell GR, Wang ZL, Campbell JH (1985) Smooth muscle phenotypic expression in human carotid arteries. Lab Invest 53: 556–562.
Pikas DS, Eriksson I, Kjellén L (2000) Overexpression of different isoforms of glucosaminyl N-deacetylase/N-sulfotransferase results in distinct heparan sulfate N-sulfation patterns. Biochemistry 39: 4552–4558.
Radhakrishnamurthy B, Srinivasan SR, Eberle K, Ruiz H, Dalferes ER, Sharma C, Berenson GS (1988) Composition of proteoglycans synthesised by rabbit aortic smooth muscle cells explants in culture and effect of experimental atherosclerosis. Biochim Biophys Acta 964: 231–243.
Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellen L, Forsberg E (2000) Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/ N-sulfotransferase-1. J Biol Chem 275: 25926–25930.
Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L (1997) Heparan sulfate proteoglycans of the cardiovascular system. J Clin Invest 99: 2062–2070.
Salmivirta M, Lidholt K, Lindahl U (1996) Heparan sulfate: A piece of information. FASEB J 10: 1270–1279.
Schmidt A, Buddecke E (1990) Bovine aortic smooth muscle cells synthesize two functionally different proteoheparan sulphate species. Exp Cell Res 189: 269–275.
Schmidt A, Lemming G, Yoshida K, Buddecke E (1992) Molecular organisation and antiproliferative domains of arterial tissue heparan sulfate. Eur J Cell Biol 59: 322–328.
Toma L, Berninsone P, Hirschberg CB (1998) The putative heparinspecific N-acetylglucosaminyl N-deacetylase/N-sulfotransferase also occurs in non-heparin-producing cells. J Biol Chem 273: 22458–22465.
Wight TN (1989) Cell Biology of Arterial Proteoglycans. Arteriosclerosis 9: 1–20.
Williams SP, Mason RM (1991) Modulation of proteoglycan synthesis by bovine vascular smooth muscle cell proliferation and treatment with heparin. Arch Biochem Biophys 287: 386–396.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bingley, J.A., Hayward, I.P., Girjes, A.A. et al. Expression of Heparan Sulphate N-deacetylase/N-sulphotransferase by Vascular Smooth Muscle Cells. Histochem J 34, 131–137 (2002). https://doi.org/10.1023/A:1020938430120
Issue Date:
DOI: https://doi.org/10.1023/A:1020938430120